These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 30040996)

  • 1. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs).
    Gelosa P; Castiglioni L; Tenconi M; Baldessin L; Racagni G; Corsini A; Bellosta S
    Pharmacol Res; 2018 Sep; 135():60-79. PubMed ID: 30040996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interactions of non-vitamin K oral anticoagulants.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1445-1461. PubMed ID: 27535163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
    Stöllberger C; Finsterer J
    Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pros and cons of new oral anticoagulants.
    Bauer KA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():464-70. PubMed ID: 24319220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
    Saraf K; Morris PD; Garg P; Sheridan P; Storey R
    Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new oral anticoagulants: a challenge for hospital formularies.
    Merli GJ
    Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
    Eek AK; Øie E; Granas AG
    Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
    De Caterina R; Lip GYH
    Clin Res Cardiol; 2017 Aug; 106(8):565-572. PubMed ID: 28396988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut.
    McMahon BJ; Kwaan HC
    Semin Thromb Hemost; 2015 Mar; 41(2):188-94. PubMed ID: 25682082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.
    Nutescu E; Chuatrisorn I; Hellenbart E
    J Thromb Thrombolysis; 2011 Apr; 31(3):326-43. PubMed ID: 21359645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
    Dzeshka MS; Lip GY
    Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.
    Pignatelli P; Pastori D; Bartimoccia S; Menichelli D; Vicario T; Nocella C; Carnevale R; Violi F
    Pharmacol Res; 2016 Nov; 113(Pt A):484-489. PubMed ID: 27693274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.